Excitation–contraction coupling inhibitors potentiate the actions of botulinum neurotoxin type A at the neuromuscular junction
Overall, our results show that the pharmacological activity of BoNT/A can be combined and synergized with other bioactive molecules and uncover a novel strategy to enhance the neuromuscular effects of BoNT/A without altering the neurotoxin moiety or intrinsic activity, thus maintaining its exceptional safety profile.
Authors
- Paul Onillon
- Mickaël Machicoane
- Marika Tonellato (ORCID: https://orcid.org/0000-0001-8402-7136)
- Marco Stazi (ORCID: https://orcid.org/0000-0002-8193-1610)
- Aram Megighian (ORCID: https://orcid.org/0000-0002-7971-5310)
- Jean‐Marc Le Doussal
- Ornella Rossetto (ORCID: https://orcid.org/0000-0002-6113-3857)
- Marco Pirazzini (ORCID: https://orcid.org/0000-0003-4127-254X)
- Marica Zainotto
- Mattia Dal Corso
Institutions
- University of Padua (IT)
Publication Details
- Journal
- British Journal of Pharmacology
- Published
- 2024-10-10
- DOI
- https://doi.org/10.1111/bph.17367
- Primary Topic
- Botulinum Toxin and Related Neurological Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Ministero dell’Istruzione, dell’Università e della Ricerca
- Università degli Studi di Padova